Echtzeit-Aktienkurs Catalent Inc.
Bid:
Ask:
Echtzeit-Chart der Catalent Inc. Aktie
Börsenkurse Catalent Inc.
New York | - | - | - | - | 63,490$ | 0,02% |
Lang & Schwarz | - | - | - | - | 60,430€ | -0,14% |
Börse Frankfurt | - | - | - | - | - | - |
Börse Stuttgart | - | - | - | - | 60,000€ | -0,88% |
Echtzeit Euro | - | - | - | - | 60,000€ | -0,66% |
USA | - | - | - | - | 63,480$ | 0,00% |
Echtzeit USD | - | - | - | - | 63,063$ | -0,66% |
gettex | - | - | - | - | 60,540€ | 0,22% |
Tradegate | - | - | - | - | 60,545€ | 0,02% |
Fundamentaldaten der Catalent Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
---|---|---|---|---|---|---|---|
2023 [USD] | 4,26 Mrd. | -342,00 Mio. | -256,00 Mio. | -1,41 | - | - | - |
2022 [USD] | 4,83 Mrd. | 605,00 Mio. | 503,00 Mio. | 2,83 | - | - | - |
2021 [USD] | 4,00 Mrd. | 715,00 Mio. | 529,00 Mio. | 3,11 | - | - | - |
2020 [USD] | 3,09 Mrd. | 260,40 Mio. | 173,00 Mio. | 1,14 | - | - | - |
2019 [USD] | 2,52 Mrd. | 160,30 Mio. | 132,00 Mio. | 0,90 | - | - | - |
2018 [USD] | 2,46 Mrd. | 152,00 Mio. | 83,60 Mio. | 0,63 | - | - | - |
2017 [USD] | 2,08 Mrd. | 135,60 Mio. | 109,80 Mio. | 0,87 | - | - | - |
2016 [USD] | 1,85 Mrd. | 144,90 Mio. | 111,50 Mio. | 0,89 | - | - | - |
2015 [USD] | 1,83 Mrd. | 112,50 Mio. | 212,20 Mio. | 1,75 | - | - | - |
2014 [USD] | 1,83 Mrd. | 67,40 Mio. | 16,20 Mio. | 0,13 | - | - | - |
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Catalent Inc. Aktie
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of techn